Literature DB >> 1374587

Persistent complement activation on tumor cells in breast cancer.

F Niculescu1, H G Rus, M Retegan, R Vlaicu.   

Abstract

The neoantigens of the C5b-9 complement complex, IgG, C3, C4, S-protein/vitronectin, fibronectin, and macrophages were localized on 17 samples of breast cancer and on 6 samples of benign breast tumors using polyclonal or monoclonal antibodies and the streptavidin-biotin-peroxidase technique. All the tissue samples with carcinoma in each the TNM stages presented C5b-9 deposits on the membranes of tumor cells, thin granules on cell remnants, and diffuse deposits in the necrotic areas. When chemotherapy and radiation therapy preceded surgery, C5b-9 deposits were more intense and extended. The C5b-9 deposits were absent in all the samples with benign lesions. S-protein/vitronectin was present as fibrillar deposits in the connective tissue matrix and as diffuse deposits around the tumor cells, less intense and extended than fibronectin. IgG, C3, and C4 deposits were present only in carcinoma samples. The presence of C5b-9 deposits is indicative of complement activation and its subsequent pathogenetic effects in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1374587      PMCID: PMC1886512     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  26 in total

1.  A molecular mechanism of complement resistance of human melanoma cells.

Authors:  M Panneerselvam; S Welt; L J Old; C W Vogel
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

2.  Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes.

Authors:  S Bhakdi; R Käflein; T S Halstensen; F Hugo; K T Preissner; T E Mollnes
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

3.  Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis.

Authors:  B P Morgan; J R Dankert; A F Esser
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

4.  Fluid-phase SC5b-8 complex of human complement: generation and isolation from serum.

Authors:  S Bhakdi; M Roth
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

5.  Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein.

Authors:  E R Podack; K T Preissner; H J Müller-Eberhard
Journal:  Acta Pathol Microbiol Immunol Scand Suppl       Date:  1984

6.  Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall.

Authors:  F Niculescu; H G Rus; D Poruţiu; V Ghiurca; R Vlaicu
Journal:  Atherosclerosis       Date:  1989-08       Impact factor: 5.162

7.  Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.

Authors:  N K Cheung; H Lazarus; F D Miraldi; C R Abramowsky; S Kallick; U M Saarinen; T Spitzer; S E Strandjord; P F Coccia; N A Berger
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

8.  Lysis of human cultured lymphoblastoid cells by cell-induced activation of the properdin pathway.

Authors:  A N Theofilopoulos; L H Perrin
Journal:  Science       Date:  1977-03-04       Impact factor: 47.728

9.  Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.

Authors:  A N Houghton; D Mintzer; C Cordon-Cardo; S Welt; B Fliegel; S Vadhan; E Carswell; M R Melamed; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

10.  Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement.

Authors:  R C Bast; P De Fabritiis; J Lipton; R Gelber; C Maver; L Nadler; S Sallan; J Ritz
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

View more
  46 in total

1.  Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death.

Authors:  L Liu; W Li; Z Li; M Kirschfink
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

2.  Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.

Authors:  V Vetvicka; B P Thornton; G D Ross
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 3.  Is complement good or bad for cancer patients? A new perspective on an old dilemma.

Authors:  Maciej M Markiewski; John D Lambris
Journal:  Trends Immunol       Date:  2009-05-08       Impact factor: 16.687

4.  Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix.

Authors:  Dae Hoon Jeong; Hyoung Kyu Kim; Abd-Ei Bary Prince; Dae Sim Lee; Young Nam Kim; Jin Han; Ki Tae Kim
Journal:  J Gynecol Oncol       Date:  2008-09-30       Impact factor: 4.401

5.  Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.

Authors:  V Vĕtvicka; M Hanikýrová; J Vĕtvicková; G D Ross
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

Review 6.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 7.  The dual role of complement in cancer and its implication in anti-tumor therapy.

Authors:  Ioannis Kourtzelis; Stavros Rafail
Journal:  Ann Transl Med       Date:  2016-07

8.  Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer.

Authors:  Stephanie Downs-Canner; Deepa Magge; Roshni Ravindranathan; Mark E O'Malley; Lily Francis; Zuqiang Liu; Z Sheng Guo; Natasa Obermajer; David L Bartlett
Journal:  Ann Surg Oncol       Date:  2015-08-20       Impact factor: 5.344

9.  Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo.

Authors:  Robert D Loberg; LaShon L Day; Rodney Dunn; Linda M Kalikin; Kenneth J Pienta
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

10.  Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas.

Authors:  J-F Mineo; A Bordron; I Quintin-Roué; S Loisel; K L Ster; V Buhé; N Lagarde; C Berthou
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.